The VP & Principal Accounting Offi of Intuitive Surgical, Inc. (ISRG), Jamie Samath Sold 861 Shares; Last Week Enanta Pharmaceuticals, Inc. (ENTA) Coverage

Jamie Samath, VP & Principal Accounting Offi of Intuitive Surgical Inc is the insider, Octafinance want to inform you for. Mr. Jamie submitted a legally required form with the Washington-based SEC disclosing a deal for 861 shares of the Pinksheet-listed Intuitive Surgical Inc, the one she is an insider in. At the time of the legal trade, the average stock price of Intuitive Surgical Inc was $420.1, making the insider stocks unloading worth $361,698 U.S. Dollars. In the last month, she also sold 964 shares with a total value of about $413,172 USD. Jamie Samath has rights to roughly 0.0008% of Intuitive Surgical Inc’s total market cap or 854 shares.

Among 6 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Enanta Pharmaceuticals Inc had 23 analyst reports since August 7, 2015 according to SRatingsIntel. Robert W. Baird maintained the shares of ENTA in report on Tuesday, August 8 with “Neutral” rating. The rating was downgraded by JP Morgan on Thursday, February 8 to “Neutral”. Robert W. Baird maintained the shares of ENTA in report on Thursday, February 8 with “Hold” rating. JMP Securities upgraded it to “Mkt Outperform” rating and $32 target in Friday, October 23 report. The company was upgraded on Tuesday, July 11 by JMP Securities. The firm has “Hold” rating by J.P. Morgan given on Thursday, February 8. The firm has “Overweight” rating by JP Morgan given on Tuesday, August 9. The firm earned “Hold” rating on Friday, October 20 by Robert W. Baird. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Underweight” rating by Barclays Capital on Friday, October 23. The firm has “Market Perform” rating given on Thursday, April 28 by JMP Securities. See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) latest ratings:

08/02/2018 Broker: J.P. Morgan Rating: Hold Downgrade
08/02/2018 Broker: Robert W. Baird Rating: Hold New Target: $82.0 Maintain
08/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
02/01/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $54 Downgrade
20/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $46.0 Maintain
20/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $58.0 Maintain
20/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $36.0 Maintain
20/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $54.0 Maintain
15/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $36.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $54 Initiates Coverage On

Analysts await Intuitive Surgical, Inc. (NASDAQ:ISRG) to report earnings on April, 17. They expect $1.60 earnings per share, up 2.56% or $0.04 from last year’s $1.56 per share. ISRG’s profit will be $179.68 million for 66.45 P/E if the $1.60 EPS becomes a reality. After $2.07 actual earnings per share reported by Intuitive Surgical, Inc. for the previous quarter, Wall Street now forecasts -22.71% negative EPS growth.

Among 20 analysts covering Intuitive Surgical Inc (NASDAQ:ISRG), 14 have Buy rating, 1 Sell and 5 Hold. Therefore 70% are positive. Intuitive Surgical Inc has $110000 highest and $290.0 lowest target. $568.57’s average target is 33.69% above currents $425.3 stock price. Intuitive Surgical Inc had 68 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, October 13 by Wells Fargo. On Monday, September 25 the stock rating was maintained by Wedbush with “Buy”. The stock of Intuitive Surgical, Inc. (NASDAQ:ISRG) has “Buy” rating given on Wednesday, April 20 by Bank of America. As per Wednesday, July 20, the company rating was maintained by Canaccord Genuity. Barclays Capital maintained the shares of ISRG in report on Wednesday, July 20 with “Overweight” rating. On Thursday, July 20 the stock rating was maintained by Piper Jaffray with “Hold”. Wedbush maintained the shares of ISRG in report on Tuesday, October 10 with “Buy” rating. The rating was downgraded by Northland Capital to “Under Perform” on Thursday, July 21. The firm earned “Hold” rating on Thursday, January 25 by Piper Jaffray. Cantor Fitzgerald maintained Intuitive Surgical, Inc. (NASDAQ:ISRG) rating on Friday, January 26. Cantor Fitzgerald has “Buy” rating and $490.0 target.

The stock increased 0.84% or $3.54 during the last trading session, reaching $425.3. About 163,674 shares traded. Intuitive Surgical, Inc. (NASDAQ:ISRG) has risen 39.52% since February 21, 2017 and is uptrending. It has outperformed by 22.82% the S&P500.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company has market cap of $47.76 billion. The company's da Vinci surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. It has a 75.01 P/E ratio. The Company’s da Vinci surgical system include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures.

Since August 22, 2017, it had 0 insider purchases, and 18 insider sales for $51.30 million activity. Shares for $6.71M were sold by SMITH LONNIE M on Tuesday, October 24. 6,000 shares valued at $2.23M were sold by MOHR MARSHALL on Monday, October 30. Another trade for 7,500 shares valued at $2.86M was made by BARRATT CRAIG H on Thursday, October 26. 7,724 shares were sold by GUTHART GARY S, worth $3.20M on Wednesday, February 7. 1,000 shares were sold by Johnson Amal M, worth $996,010. RUBASH MARK J had sold 6,750 shares worth $2.51 million on Tuesday, October 24. Another trade for 1,564 shares valued at $580,535 was sold by Samath Jamie.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.03, from 1.07 in 2017Q2. It is negative, as 35 investors sold Intuitive Surgical, Inc. shares while 190 reduced holdings. 63 funds opened positions while 170 raised stakes. 36.20 million shares or 0.41% more from 36.05 million shares in 2017Q2 were reported. Panagora Asset Management reported 1,664 shares. 40,667 are owned by Manufacturers Life The. Bridgeway Management accumulated 6,600 shares. First Tru L P, a Illinois-based fund reported 51,130 shares. State Of Wisconsin Board invested in 49,279 shares. Oklahoma-based Bokf Na has invested 0.07% in Intuitive Surgical, Inc. (NASDAQ:ISRG). Royal Retail Bank Of Canada holds 0.03% or 56,500 shares in its portfolio. 62,608 were accumulated by Strs Ohio. Zwj Invest Counsel has invested 0.04% in Intuitive Surgical, Inc. (NASDAQ:ISRG). Reilly Advsr Ltd Liability reported 5 shares. Cap Financial Advisers Ltd Llc holds 11,916 shares. Moreover, Baker Boyer Comml Bank has 1.27% invested in Intuitive Surgical, Inc. (NASDAQ:ISRG) for 368 shares. Spectrum Management Grp Inc Inc, Indiana-based fund reported 118 shares. Ohio-based Fifth Third Savings Bank has invested 0% in Intuitive Surgical, Inc. (NASDAQ:ISRG). California Pub Employees Retirement owns 0.14% invested in Intuitive Surgical, Inc. (NASDAQ:ISRG) for 91,847 shares.

The stock increased 3.71% or $2.89 during the last trading session, reaching $80.85. About 38,223 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 40.91% since February 21, 2017 and is uptrending. It has outperformed by 24.21% the S&P500.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.55 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 46.17 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: